Scarica l'app Stockscreener
30.71
1.54%
-0.48
Precedente Chiudi:
$31.19
Aprire:
$31.23
Volume 24 ore:
585.03K
Relative Volume:
1.48
Capitalizzazione di mercato:
$1.02B
Reddito:
$566.77M
Utile/perdita netta:
$48.16M
Rapporto P/E:
-83.00
EPS:
-0.37
Flusso di cassa netto:
$274.29M
1 W Prestazione:
+2.37%
1M Prestazione:
-11.50%
6M Prestazione:
-10.34%
1 anno Prestazione:
+18.75%
Intervallo 1D:
$30.67
$31.70
Intervallo di 1 settimana:
$29.80
$31.70
Portata 52W:
$25.16
$42.29
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Nome
Collegium Pharmaceutical Inc
Settore
Telefono
781-713-3699
Indirizzo
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Confronta COLL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
30.71 | 1.02B | 566.77M | 48.16M | 274.29M | -0.37 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-05-10 | Downgrade | Needham | Buy → Hold |
| 2024-05-10 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-08-25 | Reiterato | Needham | Buy |
| 2023-05-02 | Ripresa | Jefferies | Buy |
| 2022-08-08 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-14 | Iniziato | BWS Financial | Sell |
| 2020-05-27 | Iniziato | Guggenheim | Neutral |
| 2020-02-19 | Ripresa | Jefferies | Buy |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-03 | Ripresa | H.C. Wainwright | Buy |
| 2019-04-12 | Ripresa | Janney | Buy |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-03-08 | Reiterato | H.C. Wainwright | Buy |
| 2018-02-07 | Reiterato | Needham | Buy |
| 2017-12-05 | Reiterato | Needham | Buy |
| 2017-09-11 | Iniziato | H.C. Wainwright | Buy |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-09-13 | Iniziato | Gabelli & Co | Buy |
| 2015-06-01 | Iniziato | Jefferies | Buy |
| 2015-06-01 | Iniziato | Needham | Buy |
| 2015-06-01 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Collegium Pharmaceutical Inc Borsa (COLL) Ultime notizie
Rubric Capital Management LP Lowers Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Target Price at $42.60 - Defense World
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion - Seeking Alpha
Massachusetts Financial Services Co. MA Increases Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Pacer Advisors Inc. Sells 818,721 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? - MSN
Amalgamated Bank Has $372,000 Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
121,446 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Acquired by Empowered Funds LLC - MarketBeat
Victory Capital Management Inc. Purchases 215,874 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality - Simply Wall St
Collegium Pharmaceutical's (NASDAQ:COLL) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
Rubric Capital Management LP Adjusts Stake in Collegium Pharmace - GuruFocus.com
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? - MSN
Collegium Pharmaceutical Inc (COLL) Stock Price Down 3.67% on No - GuruFocus.com
Collegium to Participate in Upcoming Investor Conferences - GlobeNewswire
Collegium Pharmaceutical to Present at Major Healthcare Investor Conferences | COLL Stock News - StockTitan
Meritage Portfolio Management Purchases New Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
New York State Teachers Retirement System Lowers Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - Defense World
Principal Financial Group Inc. Has $67.46 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q3 2024 Earnings Call Transcript - Insider Monkey
Collegium Pharmaceutical Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... By GuruFocus - Investing.com Canada
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Bought by Robeco Institutional Asset Management B.V. - MarketBeat
Collegium appoints new CEO Vikram Karnani By Investing.com - Investing.com Australia
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates - MSN
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings - MSN
Collegium Pharmaceutical: Q3 Earnings Snapshot - The Washington Post
Collegium Pharmaceutical Reports Strong Q3 2024 Results - TipRanks
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Collegium Pharmaceutical Taps Vikram Karnani as CEO - MarketWatch
Collegium Pharmaceutical earnings beat by $0.04, revenue topped estimates - Investing.com UK
Collegium appoints new CEO Vikram Karnani - Investing.com
Collegium Reports Record Third Quarter 2024 Financial Results - GlobeNewswire
Collegium Appoints Vikram Karnani as Chief Executive Officer - GlobeNewswire
Collegium Pharma Names Growth Expert Karnani as CEO Amid Record Revenue Success | COLL Stock News - StockTitan
A Preview Of Collegium Pharmaceutical's Earnings - Benzinga
What To Expect From Collegium Pharmaceutical Inc (COLL) Q3 2024 Earnings - Yahoo Finance
Collegium Pharmaceutical is Now Oversold (COLL) - Nasdaq
Emerald Advisers LLC Acquires 177,129 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $42.60 Average Target Price from Analysts - Defense World
(COLL) Trading Report - Stock Traders Daily
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Collegium Pharmaceutical (COLL) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Allspring Global Investments Holdings LLC Has $3.08 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Assenagon Asset Management S.A. Sells 188,423 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) - MarketBeat
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? - MSN
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards? - MSN
Collegium Pharmaceutical Inc Azioni (COLL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.83%
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):